Recent research has made striking advances, adding to our understanding of the aethiopathogenesis of several forms of secondary osteoporosis, including those associated with rheumatic diseases and glucocorticoid treatment. Furthermore, in the last 3 years new drugs have been shown to prevent glucocorticoid-induced bone loss. Guidelines that are suitable for clinical practice have been published. Knowledge of those new opportunities and strategies, which are briefly reviewed in this article, will reduce the risk of osteoporotic fractures in rheumatic and non-rheumatic patients.
|Original language||English (US)|
|Journal||Clinical and Experimental Rheumatology|
|Issue number||5 SUPPL. 21|
|State||Published - 2000|
- Rheumatic diseases
ASJC Scopus subject areas